- Home
- WKSP vs AKTX Comparison
WKSP vs AKTX Comparison
Compare WKSP & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WKSP | AKTX |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | 81 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 11.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | WKSP | AKTX |
|---|---|---|
| Price | $1.01 | $4.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.25 | $2.53 |
| AVG Volume (30 Days) | 188.0K | ★ 329.1K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $133.45 | N/A |
| Revenue Next Year | $24.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.12 |
| 52 Week High | $4.90 | $5.50 |
Technical Indicators
Market Signals| Indicator | WKSP | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 85.60 |
| Support Level | N/A | $0.30 |
| Resistance Level | $1.44 | N/A |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.02 | 0.53 |
| Stochastic Oscillator | 16.18 | 80.85 |
Price Performance
Historical ComparisonAbout WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.